{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# PyMuPDF"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "from pyhere import here\n",
    "import pymupdf4llm\n",
    "import pandas as pd\n",
    "\n",
    "from IPython.display import display_markdown"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing /Users/kittipos/Documents/LLM/llm-notes/pdf/paper/TI-RADS_A User’s Guide.pdf...\n",
      "[                                        ] (0/9===[====                                    ] (1/9===[========                                ] (2/9====[=============                           ] (3/===[=================                       ] (4/====[======================                  ] (5/9===[==========================              ] (6/9====[===============================         ] (7/===[===================================     ] (8/====[========================================] (9/9]\n"
     ]
    }
   ],
   "source": [
    "tirads_md = pymupdf4llm.to_markdown(here(\"pdf/paper/TI-RADS_A User’s Guide.pdf\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "## Thyroid Imaging Reporting and Data System (TI-RADS): A User’s Guide[1]\n",
      "\n",
      "\n",
      "Franklin N. Tessler, MD, CM\n",
      "William D. Middleton, MD\n",
      "Edward G. Grant, MD\n",
      "\n",
      "#### An earlier incorrect version of this article appeared online and in print. This article was corrected on April 2, 2018.\n",
      "\n",
      "\n",
      "In 2017, the Thyroid Imaging Reporting and Data System\n",
      "(TI-RADS) Committee of the American College of Radiology (ACR) published a white paper that presented a\n",
      "new risk-stratification system for classifying thyroid nodules on the basis of their appearance at ultrasonography\n",
      "(US). In ACR TI-RADS, points in five feature categories\n",
      "are summed to determine a risk level from TR1 to TR5.\n",
      "Recommendations for biopsy or US follow-up are based\n",
      "on the nodule’s ACR TI-RADS level and its maximum diameter. The purpose of this article is to offer practical\n",
      "guidance on how to implement and apply ACR TI-RADS\n",
      "based on the authors’ experience with the system.\n",
      "\n",
      "q RSNA, 2018\n",
      "\n",
      "\n",
      "1 From the Department of Radiology, University of Alabama\n",
      "at Birmingham, 619 S 19th St, JT N450, Birmingham, AL\n",
      "35249 (F.N.T.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (W.D.M.);\n",
      "and Department of Radiology, Keck School of Medicine,\n",
      "University of Southern California, Los Angeles, Calif (E.G.G.).\n",
      "Received May 31, 2017; revision requested July 10;\n",
      "revision received July 22; accepted August 15; final version\n",
      "accepted August 23. Address correspondence to F.N.T.\n",
      "(e-mail: f tessler@uabmc.edu).\n",
      "\n",
      "q RSNA 2018\n",
      "\n",
      "\n",
      "-----\n",
      "\n",
      "adiologists who interpret thyroid\n",
      "ultrasonography (US) images frequently face the dilemma of how\n",
      "\n",
      "# R\n",
      "\n",
      "to report nodules, which are extremely\n",
      "common and overwhelmingly benign\n",
      "(1). Like risk-stratification systems\n",
      "from other professional societies and\n",
      "investigators, the American College of\n",
      "Radiology (ACR) Thyroid Imaging Reporting and Data System (TI-RADS)\n",
      "aims to provide an easy-to-apply\n",
      "method for practitioners to determine\n",
      "management (2). We believe that this\n",
      "will improve consistency across practices and institutions and will benefit\n",
      "patients by applying guidelines that are\n",
      "based on evidence and consensus expert opinion.\n",
      "\n",
      "ACR TI-RADS is founded on the\n",
      "\n",
      "evaluation of US features in five categories—composition, echogenicity,\n",
      "\n",
      "shape, margin, and echogenic foci—in\n",
      "which each feature is assigned 0–3\n",
      "points (Fig 1). Features in the first four\n",
      "categories each have a single score derived from mutually exclusive choices,\n",
      "whereas more than one feature may be\n",
      "present in the echogenic foci category.\n",
      "The nodule’s point total determines\n",
      "its risk level, which ranges from TR1\n",
      "(benign) to TR5 (highly suspicious).\n",
      "In conjunction with the nodule’s maximum diameter, the TR level determines\n",
      "whether to recommend a fine-needle\n",
      "aspiration (FNA) biopsy, a follow-up\n",
      "US examination, or no further action.\n",
      "As with guidelines from professional\n",
      "groups such as the American Thyroid\n",
      "Association and the Korean Society of\n",
      "Thyroid Radiology, the threshold size\n",
      "for recommending FNA decreases as\n",
      "the US features become more malignant\n",
      "\n",
      "\n",
      "ACR TI-RADS recommends formally reporting up to four thyroid nodules with\n",
      "the highest point totals. Because sonographers perform most US studies in radiology practices in the United States,\n",
      "they are often the first ones to encounter nodules. Because it is often impractical for sonographers to obtain images\n",
      "of and measure every nodule, they must\n",
      "become familiar with the criteria that\n",
      "determine which ones warrant further\n",
      "attention from the interpreting radiologist. Before the implementation of ACR\n",
      "TI-RADS, we recommend that sonographers receive in-service training that\n",
      "covers feature assignments and measurement techniques. It also may be\n",
      "helpful to post the ACR TI-RADS chart\n",
      "in the scanning rooms, especially while\n",
      "sonographers are becoming familiar\n",
      "with the five feature categories.\n",
      "\n",
      "For the patient’s initial US study, we\n",
      "\n",
      "recommend that the sonographer take\n",
      "a minute or two to obtain an overview\n",
      "\n",
      "f th ti l d t l k f d l\n",
      "\n",
      "\n",
      "appearing (3,4). Because the threshold\n",
      "diameters for mildly and moderately\n",
      "suspicious nodules (TR3 and TR4) are\n",
      "larger than in other systems, adherence\n",
      "to ACR TI-RADS will result in fewer\n",
      "biopsies of benign nodules. Inevitably,\n",
      "however, it will also result in fewer biopsies of malignant nodules, which is\n",
      "why ACR TI-RADS recommends follow-up for some nodules that do not\n",
      "meet the size criteria for FNA.\n",
      "\n",
      "Feature assignment and measure\n",
      "ment are both subject to inevitable interobserver variation. Scanning protocols\n",
      "also come into play, as nodules must be\n",
      "captured and labeled on static images\n",
      "and/or real-time clips to be classified.\n",
      "Finally, the reporting process must be\n",
      "efficient and account for circumstances\n",
      "such as patient or referring physician\n",
      "preferences, previous biopsies, interval growth, and lymphadenopathy. The\n",
      "purpose of this article is to present our\n",
      "perspective on these issues and to provide practical advice to US practitioners\n",
      "who adopt ACR TI-RADS. The opinions\n",
      "expressed are ours and do not reflect or\n",
      "imply endorsement by the ACR.\n",
      "\n",
      "\n",
      "Scanning Protocol and Labeling\n",
      "\n",
      "\n",
      "that might require further attention before capturing any images. He or she\n",
      "should then proceed to scan the entire\n",
      "gland following the sequence specified\n",
      "in the laboratory’s protocol. In this\n",
      "step, the sonographer should measure\n",
      "up to approximately four nodules that\n",
      "are likely to be reported as requiring\n",
      "biopsy or follow-up based on ACR TIRADS, as well as obtain sufficient images to document the architecture of\n",
      "the nodules.\n",
      "\n",
      "As with all sonograms, depth, gain,\n",
      "\n",
      "zoom, focal zone, frequency, pre- and\n",
      "postprocessing, dynamic range, frame\n",
      "averaging, compounding, and other\n",
      "parameters should be optimized. We\n",
      "have also found that real-time clips\n",
      "are very helpful to highlight certain\n",
      "features, notably comet-tail artifacts,\n",
      "which may become more or less conspicuous as the scanning plane traverses the nodule. Nodules of interest\n",
      "may be numbered sequentially, but if\n",
      "the sonographer identifies more than\n",
      "four, their numbering scheme may\n",
      "conflict with the one that the radiologist reports subsequently. Therefore,\n",
      "if this is the patient’s first US study,\n",
      "we recommend that the sonographer\n",
      "just label each nodule with its location\n",
      "in the gland (Fig 2). In practices that\n",
      "use worksheets, the sonographer may\n",
      "indicate the location of nodules diagrammatically to make it easier for the\n",
      "interpreting physician.\n",
      "\n",
      "If the sonogram is being performed\n",
      "\n",
      "for follow-up, whenever possible, the\n",
      "sonographer should review prior images and reports to determine if any\n",
      "nodules were described and measured.\n",
      "Not every such nodule will require\n",
      "\n",
      "\n",
      "Essentials\n",
      "\n",
      "\n",
      "n Reports need only provide struc-n\n",
      "\n",
      "tured descriptions of up to four\n",
      "nodules that warrant further\n",
      "attention.\n",
      "\n",
      "n An initial overview scan facili-n\n",
      "\n",
      "tates selection of nodules for further attention.\n",
      "\n",
      "n The position and shape of the n\n",
      "\n",
      "solid component of mixed cystic\n",
      "and solid nodules may influence\n",
      "management\n",
      "\n",
      "\n",
      "**https://doi.org/10.1148/radiol.2017171240**\n",
      "\n",
      "**Content codes:**\n",
      "\n",
      "**Radiology 2018;** 287:29–36\n",
      "\n",
      "**Abbreviations:**\n",
      "ACR = American College of Radiology\n",
      "FNA = fine-needle aspiration\n",
      "PEF = punctate echogenic foci\n",
      "TI-RADS = Thyroid Imaging Reporting and Data System\n",
      "\n",
      "Conflicts of interest are listed at the end of this article.\n",
      "\n",
      "S l th ti l b H t l i thi i\n",
      "\n",
      "\n",
      "-----\n",
      "\n",
      "Figure 1\n",
      "\n",
      "\n",
      "Figure 1: Sonographic features and associated points grouped according to the five American College of Radiology Thyroid Imaging Reporting and Data System, or\n",
      "TI-RADS, categories.\n",
      "\n",
      "\n",
      "Figure 2\n",
      "\n",
      "\n",
      "Figure 3\n",
      "\n",
      "\n",
      "Figure 2: Transverse sonogram of a nodule in\n",
      "a 61-year-old woman. The annotation shows the\n",
      "nodule’s location in the left isthmus.\n",
      "\n",
      "formal reassessment on the current\n",
      "scan, but it is helpful to know where\n",
      "to look before reimaging. Additionally,\n",
      "if the previous sonogram was reported\n",
      "by using ACR TI-RADS, nodules should\n",
      "be numbered as they were in previous\n",
      "reports. To maintain consistency, this\n",
      "applies even if a previously reported\n",
      "nodule is no longer present. For example, if one of four nodules has resolved,\n",
      "the fourth nodule should still be denoted as number 4 on the images and in\n",
      "the report.\n",
      "\n",
      "\n",
      "nodule’s volume should be occupied\n",
      "by tiny cysts (Fig 3) (5). It should be\n",
      "possible to make this determination by\n",
      "observation; if the cystic components\n",
      "comprise less than 50%, the nodule\n",
      "should not be treated as spongiform.\n",
      "Additionally, the presence of other\n",
      "features such as peripheral calcifications or macrocalcifications, which are\n",
      "usually easy to recognize, means that\n",
      "a nodule should not be classified as\n",
      "spongiform. However, the small echogenic foci that represent the back walls\n",
      "of minute cysts should not be misinterpreted as echogenic foci. Nodules with\n",
      "shadowing calcifications that preclude\n",
      "assessment of their architecture are\n",
      "assumed to be solid and therefore receive 2 points for composition.\n",
      "\n",
      "Distinguishing solid nodules from\n",
      "\n",
      "mixed cystic and solid nodules may be\n",
      "difficult in practice, as they represent\n",
      "a continuum. Unlike with spongiform\n",
      "nodules, ACR TI-RADS does not require that the observer estimate the\n",
      "percentage of a nodule that is solid, as\n",
      "this determination is often highly subjective and is less important than the\n",
      "characteristics of the solid component.\n",
      "This represents a departure from the\n",
      "lexicon, which explicitly describes predominately cystic and predominately\n",
      "solid nodules (5). As a general principle, however, otherwise-solid nodules\n",
      "that contain small cystic components\n",
      "that occupy no more than approximately 5% of the overall volume should\n",
      "be classified as solid (Fig 4).\n",
      "\n",
      "For nodules that contain more\n",
      "\n",
      "th i i l lid t d\n",
      "\n",
      "\n",
      "Feature Assignment: Improving\n",
      "Accuracy and Consistency\n",
      "\n",
      "\n",
      "As noted previously, five feature categories form the cornerstone of ACR\n",
      "TI-RADS, and so it is critical to be as\n",
      "objective as possible in applying them.\n",
      "Some features are more straightforward\n",
      "than others—for example, it is usually\n",
      "not difficult to decide whether a nod\n",
      "l i h h i h h i b t\n",
      "\n",
      "\n",
      "Figure 3: Spongiform 0.9-cm nodule in a\n",
      "59-year-old woman. More than 50% of the nodule\n",
      "is composed of small cystic spaces. The nodule\n",
      "received 0 points for composition because of its\n",
      "spongiform designation and no additional points in\n",
      "other categories ( TR1).\n",
      "\n",
      "differentiating hypoechoic from markedly hypoechoic nodules may be more\n",
      "challenging. In this section, we offer\n",
      "guidance for the most problematic features in each category. Readers may\n",
      "consult the ACR TI-RADS reporting lexicon white paper, which contains images\n",
      "illustrating many of these features (5).\n",
      "\n",
      "Composition\n",
      "\n",
      "In ACR TI-RADS, nodules classified as\n",
      "spongiform are not subject to further\n",
      "feature assignment and are treated\n",
      "as benign, with no further follow-up\n",
      "needed. Most investigators agree that\n",
      "spongiform refers to the presence of\n",
      "very small cysts that are akin to the\n",
      "fluid-filled spaces in a wet sponge, but\n",
      "there is some controversy as to how\n",
      "much of the nodule must have this appearance to qualify (6,7). Per the ACR\n",
      "th id l i t l t 50% f th\n",
      "\n",
      "\n",
      "-----\n",
      "\n",
      "Figure 4\n",
      "\n",
      "\n",
      "Figure 5\n",
      "\n",
      "\n",
      "Figure 6\n",
      "\n",
      "\n",
      "Figure 4: Sagittal sonogram of a 4.6-cm benign\n",
      "colloid nodule in a 65-year-old woman. It was\n",
      "classified as solid (composition score of 2), although\n",
      "small cystic components were present. With 1\n",
      "more point for isoechogenicity and none in other\n",
      "categories, its point total was 3 ( TR3).\n",
      "\n",
      "\n",
      "Figure 6: Benign mixed cystic and solid nodule\n",
      "(1 point) in a 40-year-old woman. The 1-point\n",
      "isoechoic solid component is distributed around the\n",
      "periphery. The nodule received 2 points ( TR2).\n",
      "\n",
      "shows that the solid material represents viable tissue rather than blood\n",
      "clot, debris, or necrotic tissue.\n",
      "\n",
      "Echogenicity\n",
      "\n",
      "Assigning echogenicity by using the\n",
      "adjacent thyroid parenchyma as a\n",
      "frame of reference is usually straightforward. However, relative reflectivity may vary considerably depending\n",
      "on scanning parameters, particularly\n",
      "gain, transmit frequency, compression, and pre- and postprocessing.\n",
      "When in doubt, we find it helpful\n",
      "to consider echogenicity in multiple\n",
      "planes of section. Real-time clips are\n",
      "valuable in problematic nodule assessments. Because hyperechoic and\n",
      "isoechoic nodules both receive 1 point\n",
      "in ACR TI-RADS, distinguishing them\n",
      "is not crucial. However, it is important to differentiate hypoechoic from\n",
      "markedly hypoechoic nodules, as the\n",
      "latter feature receives 1 additional\n",
      "point in this category. Nodules that\n",
      "are definitively less reflective than the\n",
      "anterior neck muscles, which should\n",
      "be visible on every image, are classified as markedly hypoechoic (Fig 7).\n",
      "Here, too, scanning parameters play\n",
      "a critical role, so it may be useful to\n",
      "obtain images at various gain settings.\n",
      "This maneuver may also facilitate\n",
      "identification of completely anechoic\n",
      "cysts that otherwise mimic markedly\n",
      "hypoechoic nodules. Conversely, the\n",
      "presence of flow within a uniformly\n",
      "hypoechoic nodule confidently charac-i\n",
      "\n",
      "\n",
      "Figure 7\n",
      "\n",
      "\n",
      "Figure 7: Transverse sonogram shows 2.0-cm\n",
      "markedly hypoechoic papillary carcinoma (arrows) in\n",
      "a 24-year-old woman. The nodule received 2 points\n",
      "for solid composition and 3 for marked hypoechogenicity, totaling 5 points ( TR4).\n",
      "\n",
      "are therefore categorized as mixed\n",
      "cystic and solid, the appearance of\n",
      "the solid component helps determine\n",
      "management. For example, the presence of punctate echogenic foci (PEF)\n",
      "or macro- or peripheral calcifications\n",
      "increases the nodule’s suspicion level\n",
      "(8,9). These and other suspicious features that also apply to uniformly solid\n",
      "nodules contribute to the point score\n",
      "of mixed cystic and solid nodules. In\n",
      "addition, the nodule’s maximum dimension, not the size of its solid component, governs recommendations. If\n",
      "the solid component is smaller than\n",
      "the size threshold for a completely\n",
      "solid nodule at a given TR level but the\n",
      "overall nodule is above the cutoff, FNA\n",
      "\n",
      "\n",
      "Figure 5: Mixed cystic and solid papillary cancer\n",
      "in a 39-year-old man has a lobulated solid mural\n",
      "component with punctate echogenic foci (PEF). The\n",
      "nodule received 1 point for composition, 1 for its\n",
      "isoechoic solid component, and 3 for PEF, for a total\n",
      "of 5 ( TR4).\n",
      "\n",
      "with suspicious solid tissue that are\n",
      "too small to warrant FNA will still usually require US follow-up, lessening the\n",
      "likelihood that clinically important malignancy will remain undetected in the\n",
      "long term.\n",
      "\n",
      "Other characteristics of the solid\n",
      "\n",
      "components, including their position\n",
      "and shape, should also be considered.\n",
      "Position refers to the location and\n",
      "symmetry of the solid material relative to the whole nodule. Mural nodules that are isolated, masslike, and\n",
      "protrude into the fluid are more suspicious. Shape refers to the interface\n",
      "between the solid component and adjacent fluid. As with solid nodules, lobulation is a suspicious finding (Fig 5).\n",
      "Conversely, solid material that is relatively smooth and more-or-less evenly\n",
      "distributed around the periphery of a\n",
      "nodule is less concerning (Fig 6). Some\n",
      "authors have also called attention to\n",
      "the interface between solid mural components and the cyst wall, with acute\n",
      "angles being more worrisome (10,11).\n",
      "Position and shape do not contribute to\n",
      "the nodule’s point total, but if the solid\n",
      "component exhibits any of these suspicious features, we occasionally recommend FNA even if the nodule does not\n",
      "otherwise meet criteria for biopsy. The\n",
      "presence of flow at color or power Doppler imaging does not reliably indicate\n",
      "that the solid component is malignant,\n",
      "nor does its absence mean that it is be\n",
      "\n",
      "-----\n",
      "\n",
      "Figure 8\n",
      "\n",
      "\n",
      "Figure 9\n",
      "\n",
      "\n",
      "Figure 8: Transverse sonogram of a taller-thanwide papillary cancer in a 47-year-old man. In\n",
      "addition to 3 points for shape, the nodule warranted 2 points for solid composition, 1 point for\n",
      "isoechogenicity, and 3 points for numerous punctate\n",
      "echogenic foci, for a total of 9 points ( TR5).\n",
      "\n",
      "\n",
      "Figure 9: Transverse sonogram in a 52-year-old\n",
      "woman shows a benign follicular nodule with a\n",
      "smooth margin (arrows). The nodule was assigned 2\n",
      "points for solid composition and 1 for isoechogenicity,\n",
      "for a total of 3 points ( TR3).\n",
      "\n",
      "\n",
      "therefore suspicious (12). We also note\n",
      "that nodules that are perfectly round\n",
      "in cross section are technically neither\n",
      "wider-than-tall nor taller-than-wide.\n",
      "When that occurs, it is acceptable to\n",
      "report the nodule as either wider-thantall or not taller-than-wide. Rarely, it\n",
      "may be appropriate to assess this characteristic on a sagittal image if a nodule\n",
      "is obliquely oriented in that plane, as it\n",
      "may be round in cross section.\n",
      "\n",
      "Margin\n",
      "\n",
      "A nodule’s margin, defined as the character of its interface with adjacent intraor extrathyroidal tissue, is best appreciated along its anterior border, which\n",
      "is orthogonal to the ultrasound beam.\n",
      "This is facilitated by scanning with the\n",
      "depth adjusted to show the part of the\n",
      "nodule closest to the transducer. A\n",
      "smooth margin is characterized by an\n",
      "even, gradually curving interface (Fig 9).\n",
      "If lobulation, angulation, or intrusion of\n",
      "the nodule’s solid component into the\n",
      "surrounding tissue is present to any\n",
      "extent, the margin should be classified\n",
      "as lobulated or irregular; both warrant\n",
      "2 points, so it is not important to distinguish them (Fig 10). Extrathyroidal\n",
      "extension is a 3-point feature that is\n",
      "characterized by clear-cut invasion of\n",
      "adjacent structures. This appearance,\n",
      "which is pathognomonic for malignancy, should not be recorded merely\n",
      "because a nodule bulges the border of\n",
      "the thyroid gland (Fig 11). US clips may\n",
      "be helpful to demonstrate that a nodule\n",
      "truly invades the soft tissues, as they\n",
      "will be fixed as the transducer moves.\n",
      "If the nodule’s border is not depicted\n",
      "clearly, it is categorized as ill defined\n",
      "and receives 0 points for margin, as this\n",
      "is not a discriminatory feature.\n",
      "\n",
      "Echogenic Foci\n",
      "\n",
      "Macrocalcifications and peripheral calcifications rarely present diagnostic\n",
      "problems, as they are usually associated with at least some degree of acoustic shadowing. However, PEF, which\n",
      "may represent psammoma bodies in\n",
      "papillary cancers, are less straightforward. Many PEF are not psammomatous and actually represent the back\n",
      "\n",
      "ll f i t t Additi ll th\n",
      "\n",
      "\n",
      "Figure 10\n",
      "\n",
      "\n",
      "Figure 10: (a) Sagittal image of a 2.2-cm carcinoma in a 61-year-old man shows a lobulated margin (arrows),\n",
      "a 2-point feature. The nodule also received 2 points for solid composition and 2 for hypoechogenicity, for a total of\n",
      "6 points ( TR4). (b) Sagittal sonogram of a 1.2 cm carcinoma with an irregular (spiculated) margin in a 39-year-old\n",
      "woman. In addition to 2 points for its irregular margin, the nodule was assigned 2 points for solid composition, 3\n",
      "points for very low echogenicity, and 3 points for punctate echogenic foci, for a total of 10 points ( TR5).\n",
      "\n",
      "\n",
      "Figure 11\n",
      "\n",
      "\n",
      "Figure 11: Papillary carcinoma bulging the thyroid\n",
      "border in a 24-year-old woman. No invasion was\n",
      "demonstrated at surgery. The nodule received 2\n",
      "points for solid composition, 2 for hypoechogenicity,\n",
      "3 for taller-than-wide shape, and 2 for a lobulated\n",
      "margin Its point total was 9 (TR5)\n",
      "\n",
      "\n",
      "makes it impossible to determine a\n",
      "nodule’s echogenicity, it is assumed to\n",
      "be at least isoechoic or hyperechoic\n",
      "and receives 1 point in this category.\n",
      "\n",
      "Shape\n",
      "\n",
      "Like echogenicity, a nodule’s shape\n",
      "(wider-than-tall or taller-than-wide) is\n",
      "rarely difficult to define. “Tallness” refers to a nodule’s anteroposterior dimension and “width” to its transverse\n",
      "dimension on an axial image. A gestalt\n",
      "impression of whether a nodule is taller-than-wide is usually sufficient (Fig 8).\n",
      "The goal is to ascertain whether the\n",
      "nodule has grown more front-to-back\n",
      "than side-to-side, which suggests that\n",
      "it h i l t d ti l d i\n",
      "\n",
      "\n",
      "-----\n",
      "\n",
      "speckle pattern of normal or nonmalignant thyroid tissue may at times\n",
      "contain minute bright dots that should\n",
      "not be misinterpreted as PEF (Fig 12).\n",
      "Therefore, we do not report them unless they are discrete and appear only\n",
      "within the nodule, not in adjacent thyroid tissue. This pitfall may be avoided\n",
      "by scrutinizing the suspicious tissue\n",
      "and adjacent parenchyma. If dots are\n",
      "present in both, they are probably not\n",
      "PEF for the purpose of ACR TI-RADS\n",
      "classification. The only exception is the\n",
      "diffuse sclerosing variant of papillary\n",
      "carcinoma, which should not present a\n",
      "problem in diagnosis (13).\n",
      "\n",
      "ACR TI-RADS distinguishes be\n",
      "tween small and large comet-tail artifacts. The latter, which are larger than\n",
      "1 mm and are V shaped, are associated\n",
      "with colloid and are reliable signs of benignity when found in the cystic components of nodules. On the other hand,\n",
      "small comet-tail artifacts should be\n",
      "treated as PEF and therefore receive 3\n",
      "points when embedded in hypoechoic,\n",
      "solid tissue (Fig 13) (14). If both types\n",
      "coexist in a nodule, the more suspicious\n",
      "one determines how many points to assign. The central tenet is that the mere\n",
      "presence of any comet-tail artifacts\n",
      "should not be grounds for concluding\n",
      "that a nodule is benign.\n",
      "\n",
      "When different types of echogenic\n",
      "\n",
      "foci are present, the points for each type\n",
      "are summed to determine the overall\n",
      "point total for echogenic foci. For instance, a nodule containing both peripheral calcifications and macrocalcifications\n",
      "would be assigned 3 points in this category (1 point for macrocalcifications plus\n",
      "2 points for peripheral calcifications).\n",
      "This differs from the other categories, in\n",
      "which the single finding with the highest\n",
      "point value is used to determine the point\n",
      "assignment for that feature.\n",
      "\n",
      "\n",
      "Figure 12\n",
      "\n",
      "\n",
      "Figure 13\n",
      "\n",
      "\n",
      "Reports of thyroid sonograms should\n",
      "include the following elements:\n",
      "\n",
      "1. Tridimensional measurements of\n",
      "\n",
      "the right and left lobes and the anteroposterior dimension of the isthmus.\n",
      "\n",
      "2. An overall description of the thy\n",
      "roid parenchyma.\n",
      "\n",
      "3. Formal description of up to the\n",
      "\n",
      "four most suspicious nodules.\n",
      "\n",
      "4. Recommendations for\n",
      "\n",
      "manage­ment.\n",
      "\n",
      "Nodules not reported formally may\n",
      "\n",
      "be mentioned in the overall description\n",
      "by calling attention to them and stating that none warrant FNA or follow-up\n",
      "US per ACR TI-RADS. The sole exception is when a US study is performed\n",
      "to evaluate a nodule that was palpated\n",
      "or detected at another imaging examination. Even if no further action is required, the nodule in question should\n",
      "be formally reported, along with any\n",
      "suspicious incidental nodules.\n",
      "\n",
      "Per ACR TI-RADS, glands that con\n",
      "tain multiple nodules with similar US\n",
      "characteristics usually do not warrant\n",
      "biopsy because it is impractical to sample every nodule. There is no evidence\n",
      "to suggest that performing FNA on the\n",
      "largest nodule improves patient out\n",
      "F hi d\n",
      "\n",
      "\n",
      "Figure 13: Small comet-tail artifacts and\n",
      "additional echogenic foci (punctate echogenic foci\n",
      "\n",
      "[PEF ]) in a papillary carcinoma in a 54-year-old\n",
      "woman. In addition to 3 points for PEF, the nodule\n",
      "was assigned 2 points for solid composition, 2 for\n",
      "hypoechogenicity, and 2 for a lobulated margin, for a\n",
      "total of 9 points ( TR5).\n",
      "\n",
      "When this occurs, this limitation should\n",
      "be noted in the report.\n",
      "\n",
      "\n",
      "Reporting Considerations\n",
      "\n",
      "\n",
      "Measuring Nodules: How to Reduce\n",
      "Errors\n",
      "\n",
      "\n",
      "ACR TI-RADS recommends measuring\n",
      "a nodule’s longest axis and the largest\n",
      "dimension perpendicular to the longest\n",
      "axis on a transverse (axial) image and\n",
      "the largest craniocaudal dimension on\n",
      "\n",
      "itt l i Th t\n",
      "\n",
      "\n",
      "Figure 12: Sonogram of the left thyroid lobe in\n",
      "a 42-year-old man. Minute bright dots representing the speckle pattern of normal or nonmalignant\n",
      "tissue (arrow) should not be misinterpreted as\n",
      "punctate echogenic foci.\n",
      "\n",
      "usually lie parallel or perpendicular to\n",
      "the sound beam, but they will be angled\n",
      "if the nodule is obliquely oriented. Regardless, nodules should be measured\n",
      "by using the same technique that was\n",
      "used in prior studies to assess growth,\n",
      "which may be based on changes in linear measurements or volume.\n",
      "\n",
      "To improve consistency on follow-up\n",
      "\n",
      "examinations, sonographers/sonologists\n",
      "should review prior sonograms to determine which nodules may warrant continued attention and see how they were\n",
      "measured. Current US systems equipped\n",
      "with high-frequency linear array transducers achieve very high spatial resolution. In practice, however, measurement\n",
      "accuracy is hampered by interobserver\n",
      "variability that is chiefly related to poor\n",
      "border conspicuity. This limitation, which\n",
      "is a property of the interface between the\n",
      "nodule and its surroundings, can be mitigated by meticulous technique, but not\n",
      "eliminated entirely.\n",
      "\n",
      "As with other features, scanning pa\n",
      "rameters play an important role. Notably,\n",
      "settings that would be inappropriate for\n",
      "characterizing internal architecture may\n",
      "enhance the visibility of a nodule’s margin. For example, lowering the dynamic\n",
      "range or altering pre- and postprocessing\n",
      "settings may make it easier to distinguish\n",
      "the nodule from adjacent tissue, making\n",
      "it easier to tell where to place measurement calipers. Despite the imager’s best\n",
      "efforts, however, some nodules cannot be\n",
      "measured reliably if they are poorly defi d d i h h i di\n",
      "\n",
      "\n",
      "-----\n",
      "\n",
      "that at least a brief assessment of\n",
      "nodes may be helpful in determining\n",
      "the need for biopsy in the setting of\n",
      "thyroid nodules. This practice is in\n",
      "keeping with scanning protocols from\n",
      "professional organizations (3,4). If a\n",
      "node has a suspicious appearance,\n",
      "but there are no thyroid nodules that\n",
      "warrant FNA, the node should be\n",
      "sampled. In some patients, it may be\n",
      "appropriate to biopsy a suspicious\n",
      "nodule that does not meet the size\n",
      "threshold for its ACR TI-RADS level.\n",
      "A comprehensive evaluation of nodes\n",
      "is required in patients known to have\n",
      "or suspected of having thyroid cancer.\n",
      "It may be performed at the time of the\n",
      "initial thyroid US examination, in conjunction with a US-guided biopsy, or\n",
      "as a separate preoperative US evaluation after a cancer diagnosis has been\n",
      "made with biopsy.\n",
      "\n",
      "ACR TI-RADS does not specify\n",
      "\n",
      "what to recommend for nodules that\n",
      "have been sampled previously. Radiologists may defer decisions regarding follow-up US or repeat FNA to\n",
      "referring physicians, who may have\n",
      "information regarding previous biopsy results that are unavailable to\n",
      "the radiologist interpreting a thyroid\n",
      "sonogram. Decisions regarding the\n",
      "need for repeat biopsy will usually be\n",
      "made by the referring physician based\n",
      "on guidelines from the American Thyroid Association or other professional\n",
      "groups (3).\n",
      "\n",
      "It is also important to recognize\n",
      "\n",
      "that even benign nodules may assume a more suspicious appearance\n",
      "following biopsy, causing them to\n",
      "appear more solid, hypoechoic, or\n",
      "calcified. These so-called mummified nodules will have a higher ACR\n",
      "TI-RADS score, but recent evidence\n",
      "suggests that such nodules should be\n",
      "approached more conservatively and\n",
      "can likely be safely followed with US\n",
      "rather than repeat FNA, regardless of\n",
      "their score (17).\n",
      "\n",
      "\n",
      "ACR TI-RADS borrows from the\n",
      "American Thyroid Association guideli d d fi li i ll i t t\n",
      "\n",
      "\n",
      "Figure 14\n",
      "\n",
      "\n",
      "Figure 14: Structured template for American College of Radiology (ACR) Thyroid Imaging Reporting\n",
      "and Data System ( TI-RADS) reporting.\n",
      "\n",
      "against the designation “dominant\n",
      "\n",
      "nodule,” which is often applied to the\n",
      "largest nodule in the gland. Biopsy is\n",
      "recommended only if one or two nodules have high point totals that would\n",
      "warrant FNA, regardless of whether\n",
      "multiple nodules are present.\n",
      "\n",
      "We have found that formal report\n",
      "ing is faster with structured report templates that include the elements in ACR\n",
      "TI-RADS (Fig 14). Such templates are\n",
      "easy to implement in any voice recognition system. With practice, we have\n",
      "found that it takes no more than approximately 20 seconds to report each\n",
      "nodule. This approach also makes it easier for referring physicians to read and\n",
      "understand reports, as well as to implement quality assurance and control procedures and peer review.\n",
      "\n",
      "The ACR TI-RADS chart provides\n",
      "\n",
      "descriptors for each of the five suspicion levels: benign (TR1), not suspicious (TR2), mildly suspicious (TR3),\n",
      "moderately suspicious (TR4), and\n",
      "\n",
      "highly suspicious (TR5). In a recent\n",
      "study, they were associated with aggregate cancer risks of 0.3%, 1.5%, 4.8%,\n",
      "9.1%, and 35.0%, respectively (15).\n",
      "The ACR TI-RADS recommendations\n",
      "for FNA and follow-up were in part informed by the growing recognition that\n",
      "many thyroid cancers are indolent and\n",
      "unlikely to cause harm to patients duri th i lif ti (16) N th l\n",
      "\n",
      "\n",
      "recognize that patients are increasingly\n",
      "able to view imaging reports though\n",
      "portals and other means and that they\n",
      "may be concerned that an 8-mm TR4\n",
      "nodule described as “moderately suspicious” will not be sampled for biopsy\n",
      "or even followed up. For this reason,\n",
      "radiologists may elect not to mention\n",
      "the risk descriptors in reports.\n",
      "\n",
      "By no means are we advocating\n",
      "\n",
      "withholding information; rather, we\n",
      "wish to avoid misinterpretation by patients who may not fully understand\n",
      "the difference in clinical importance\n",
      "between a moderately suspicious thyroid nodule and a similarly suspicious\n",
      "pulmonary lesion. Alternatively, radiologists may report aggregate risks or\n",
      "risk ranges. We also believe that radiologists should discuss reporting preferences with referring physicians to avoid\n",
      "misunderstandings.\n",
      "\n",
      "Every report that includes one or\n",
      "\n",
      "more formally reported nodules must\n",
      "also provide recommendations for management, whether FNA, follow-up US,\n",
      "or no further action. We believe that\n",
      "statements such as “clinical correlation is\n",
      "needed to determine the need for biopsy”\n",
      "should be avoided. Endocrinologists and\n",
      "other referring physicians should be expected to apply reasonable standard-ofcare principles in deciding whether to follow the radiologist’s recommendations.\n",
      "For example, a highly suspicious nodule\n",
      "in a patient with a limited life expectancy\n",
      "or other issues may not require biopsy.\n",
      "\n",
      "Conversely, patient or referring\n",
      "\n",
      "physician preferences may at times\n",
      "warrant deviation from the strict ACR\n",
      "TI-RADS guidelines. Patients with a\n",
      "strong personal or family history that\n",
      "increases the likelihood of cancer, or\n",
      "patients who are highly concerned for\n",
      "other reasons, may require FNA and/or\n",
      "follow-up of nodules that fall below\n",
      "ACR TI-RADS size thresholds. This involves the radiologist in shared decision\n",
      "making that is appropriate for effective\n",
      "medical care. Similarly, ACR TI-RADS\n",
      "recommends FNA of no more than two\n",
      "nodules in one gland, but circumstances\n",
      "may rarely require tissue sampling of\n",
      "more than two nodules.\n",
      "\n",
      "ACR TI-RADS does not encompass\n",
      "\n",
      "i l l h d b t b li\n",
      "\n",
      "\n",
      "Growth and Follow-up\n",
      "\n",
      "\n",
      "-----\n",
      "\n",
      "growth as a 20% increase in at least\n",
      "two nodule dimensions and a minimal increase of 2 mm, or a 50% or\n",
      "greater increase in volume (3). If a\n",
      "nodule enlarges to the point where\n",
      "it exceeds the size threshold for its\n",
      "ACR TI-RADS level, we recommend\n",
      "FNA, if this has not already been\n",
      "performed. Although rapid enlargement is suspicious, growth does not\n",
      "reliably distinguish between benign\n",
      "and malignant nodules (18). However,\n",
      "nodules that do not grow substantially\n",
      "over the course of 5 years (based on\n",
      "comparison between initial and 5-year\n",
      "sonograms) may be considered benign. Nodules that exhibit an interval\n",
      "increase in ACR TI-RADS level but\n",
      "remain below the size threshold for\n",
      "FNA should be imaged with follow-up\n",
      "US in 1 year.\n",
      "\n",
      "\n",
      "lignancy. Korean J Radiol 2012;13(5):530–\n",
      "535.\n",
      "\n",
      "10. Kim DW, Lee EJ, In HS, Kim SJ. Sono\n",
      "graphic differentiation of partially cystic thyroid nodules: a prospective study. AJNR Am\n",
      "J Neuroradiol 2010;31(10):1961–1966.\n",
      "\n",
      "11. Kim DW, Park JS, In HS, Choo HJ, Ryu\n",
      "\n",
      "JH, Jung SJ. Ultrasound-based diagnostic\n",
      "classification for solid and partially cystic\n",
      "thyroid nodules. AJNR Am J Neuroradiol\n",
      "2012;33(6):1144–1149.\n",
      "\n",
      "12. Kim EK, Park CS, Chung WY, et al. New\n",
      "\n",
      "sonographic criteria for recommending\n",
      "fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J\n",
      "Roentgenol 2002;178(3):687–691.\n",
      "\n",
      "13. Jung HK, Hong SW, Kim EK, Yoon JH,\n",
      "\n",
      "Kwak JY. Diffuse sclerosing variant of papillary thyroid carcinoma: sonography and\n",
      "specimen radiography. J Ultrasound Med\n",
      "2013;32(2):347–354.\n",
      "\n",
      "14. Malhi H, Beland MD, Cen SY, et al. Echo\n",
      "genic foci in thyroid nodules: significance\n",
      "of posterior acoustic artifacts. AJR Am J\n",
      "Roentgenol 2014;203(6):1310–1316.\n",
      "\n",
      "15. Middleton WD, Teefey SA, Reading CC, et\n",
      "\n",
      "al. Multiinstitutional analysis of thyroid nodule risk stratification using the American\n",
      "College of Radiology Thyroid Imaging Reporting and Data System. AJR Am J Roentgenol 2017;208(6):1331–1341.\n",
      "\n",
      "16. Brito JP, Davies L, Zeballos-Palacios C,\n",
      "\n",
      "Morris JC, Montori VM. Papillary lesions\n",
      "of indolent course: reducing the overdiagnosis of indolent papillary thyroid cancer\n",
      "and unnecessary treatment. Future Oncol\n",
      "2014;10(1):1–4.\n",
      "\n",
      "17. Lacout A, Chevenet C, Marcy PY. Mummi\n",
      "fied thyroid syndrome. AJR Am J Roentgenol 2016;206(4):837–845.\n",
      "\n",
      "18. Ajmal S, Rapoport S, Ramirez Batlle H,\n",
      "\n",
      "Mazzaglia PJ. The natural history of the\n",
      "benign thyroid nodule: what is the appropriate follow-up strategy? J Am Coll Surg\n",
      "2015;220(6):987–992.\n",
      "\n",
      "\n",
      "Conclusion\n",
      "\n",
      "\n",
      "The ACR TI-RADS risk-stratification\n",
      "system allows practitioners to determine whether thyroid nodules require\n",
      "biopsy, follow-up, or no further action\n",
      "based on their US appearance. Success demands close cooperation between radiologists and sonographers,\n",
      "understanding of the nuances and pitfalls of feature assignments, and attention to detail in reporting and making\n",
      "recommendations.\n",
      "\n",
      "**Disclosures of Conflicts of Interest: F.N.T.**\n",
      "Activities related to the present article: disclosed no relevant relationships. Activities not\n",
      "related to the present article: author received\n",
      "payment from North Carolina Radiological\n",
      "Society to lecture on ACR TI-RADS at ultrasound course. Other relationships: disclosed\n",
      "no relevant relationships. W.D.M. disclosed\n",
      "no relevant relationships. E.G.G. disclosed no\n",
      "relevant relationships.\n",
      "\n",
      "\n",
      "References\n",
      "\n",
      "1. Burch HB, Burman KD, Cooper DS, Hen\n",
      "nessey JV, Vietor NOA. A 2015 survey of\n",
      "clinical practice patterns in the management\n",
      "of thyroid nodules. J Clin Endocrinol Metab\n",
      "2016;101(7):2853–2862.\n",
      "\n",
      "2. Tessler FN, Middleton WD, Grant EG, et\n",
      "\n",
      "al. ACR thyroid imaging, reporting and\n",
      "data system (TI-RADS): white paper of the\n",
      "ACR TI-RADS committee. J Am Coll Radiol\n",
      "2017;14(5):587–595.\n",
      "\n",
      "3. Haugen BR, Alexander EK, Bible KC, et al.\n",
      "\n",
      "2015 American Thyroid Association management guidelines for adult patients with\n",
      "thyroid nodules and differentiated thyroid\n",
      "cancer: the American Thyroid Association\n",
      "Guidelines Task Force on Thyroid Nodules\n",
      "and Differentiated Thyroid Cancer. Thyroid\n",
      "2016;26(1):1–133.\n",
      "\n",
      "4. Shin JH, Baek JH, Chung J, et al. Ultraso\n",
      "nography diagnosis and imaging-based management of thyroid nodules: revised Korean\n",
      "Society of Thyroid Radiology consensus\n",
      "statement and recommendations. korean J\n",
      "Radiol 2016;17(3):370–395.\n",
      "\n",
      "5. Grant EG, Tessler FN, Hoang JK, et al. Thy\n",
      "roid ultrasound reporting lexicon: white paper of the ACR Thyroid Imaging, Reporting\n",
      "and Data System (TIRADS) Committee. J\n",
      "Am Coll Radiol 2015;12(12 Pt A):1272–1279.\n",
      "\n",
      "6. Moon WJ, Jung SL, Lee JH, et al. Benign\n",
      "\n",
      "and malignant thyroid nodules: US differentiation—multicenter retrospective study.\n",
      "Radiology 2008;247(3):762–770.\n",
      "\n",
      "7. Bonavita JA, Mayo J, Babb J, et al. Pat\n",
      "tern recognition of benign nodules at ultrasound of the thyroid: which nodules\n",
      "can be left alone? AJR Am J Roentgenol\n",
      "2009;193(1):207–213.\n",
      "\n",
      "8. Lee MJ, Kim EK, Kwak JY, Kim MJ. Par\n",
      "tially cystic thyroid nodules on ultrasound:\n",
      "probability of malignancy and sonographic\n",
      "differentiation. Thyroid 2009;19(4):341–346.\n",
      "\n",
      "9. Park JM, Choi Y, Kwag HJ. Partially cystic\n",
      "\n",
      "thyroid nodules: ultrasound findings of ma\n",
      "\n",
      "-----\n",
      "\n",
      "mri-burn-prevention-poster/. Published November 16, 2015. Accessed January 25,\n",
      "2018.\n",
      "\n",
      "5. Expert Panel on MR Safety, Kanal E, Barkov\n",
      "ich AJ, et al. ACR guidance document on MR\n",
      "safe practices: 2013. J Magn Reson Imaging\n",
      "2013;37(3):501–530.\n",
      "\n",
      "Biparametric Prostate MR Imaging Protocol: Time to Revise PI-RADS Version 2?\n",
      "\n",
      "From\n",
      "Arnaldo Stanzione, MD, Sirio Cocoz\n",
      "za, MD, Renato Cuocolo, MD, and\n",
      "Massimo Imbriaco, MD\n",
      "\n",
      "Department of Advanced Biomedical\n",
      "\n",
      "Sciences, Federico II University\n",
      "of Naples, Via Pansini 5, Naples\n",
      "80131, Italy\n",
      "e-mail: massimo.imbriaco@unina.it\n",
      "\n",
      "Editor:\n",
      "\n",
      "With great interest, we read the Letters to the Editor by Dr Scialpi and colleagues (1) in the January 2018 issue\n",
      "of Radiology and Drs Kaji and Inamura\n",
      "(2) in the February 2018 issue of Radi_ology commenting on the article by Dr_\n",
      "Kuhl et al in the July 2017 issue of Ra_diology (3) about a possible reduction_\n",
      "in acquisition time of multiparametric\n",
      "magnetic resonance (MR) imaging of\n",
      "the prostate. In particular, Dr Kuhl and\n",
      "colleagues investigated the diagnostic\n",
      "accuracy of a shortened biparametric\n",
      "MR imaging protocol composed by the\n",
      "sole evaluation of axial T2-weighted and\n",
      "diffusion-weighted imaging. The authors showed how this approach led to\n",
      "a similar diagnostic performance in the\n",
      "detection of prostatic lesions compared\n",
      "with the standard multiparametric MR\n",
      "imaging protocol. In the first letter, Dr\n",
      "Scialpi and colleagues (1) pointed out\n",
      "that the elimination of sagittal and coronal T2-weighted images could make\n",
      "it difficult to measure both prostate\n",
      "and lesion volume, as well as to perform targeted biopsy when using fusion systems that require these planes.\n",
      "Furthermore, Dr Scialpi and colleagues\n",
      "suggested that the sagittal plane is essential for the assessment of extraglandular disease. On the other hand, Drs\n",
      "Kaji and Inamura pointed out that, in\n",
      "\n",
      "\n",
      "the article by Dr Kuhl and colleagues,\n",
      "patients were considered having a positive index test result when they had a\n",
      "Prostate Imaging Reporting and Data\n",
      "System (PI-RADS) score of 3, 4, or 5\n",
      "(2–3). In this setting, considering that\n",
      "dynamic contrast-enhanced (DCE)\n",
      "\n",
      "evaluation allows only for an upgrade\n",
      "of PI-RADS score from 3 to 4 (4), it\n",
      "is clear that its possible contribution to\n",
      "a correct diagnostic assessment is not\n",
      "significant. Our opinion, which is consistent with data available in the literature, is that biparametric MR imaging\n",
      "offers clear and significant advantages\n",
      "over standard multiparametric MR imaging, providing a similar diagnostic accuracy but leading to a significant reduction of acquisition time, which is\n",
      "directly related to both patient discomfort and costs (5). Future studies are\n",
      "strongly warranted to better identify\n",
      "and evaluate all possible strategies and\n",
      "combination of T2-weighted imaging\n",
      "and diffusion-weighted imaging, considering all advantages and disadvantages of their combination. However, in\n",
      "the transition from PI-RADS version 1\n",
      "to PI-RADS version 2, the role of MR\n",
      "spectroscopy and DCE imaging was already reappraised and reduced, and at\n",
      "the time further concerns regarding the\n",
      "usefulness of DCE were raised (6). In\n",
      "light of the recently published articles\n",
      "on shortened biparametric MR imaging\n",
      "prostatic protocols (3,5,7), our opinion\n",
      "is that DCE should no longer be considered mandatory and its role further revised within a new and up-to-date version of PI-RADS.\n",
      "\n",
      "**Disclosures of Conflicts of Interest: A.S. dis-**\n",
      "closed no relevant relationships. **S.C. Activities**\n",
      "related to the present article: disclosed no relevant relationships. Activities not related to the\n",
      "present article: received payment for lectures\n",
      "including service on speakers bureaus from\n",
      "Sanofi Genzyme. Other relationships: disclosed\n",
      "no relevant relationships. R.C. disclosed no relevant relationships. **M.I. disclosed no relevant**\n",
      "relationships.\n",
      "\n",
      "References\n",
      "\n",
      "1. Scialpi M, Martorana E, Aisa MC, Rondoni\n",
      "\n",
      "V, D’Andrea A, Brunese L. Abbreviated biparametric prostate MR imaging: is it really an\n",
      "alternative to multiparametric MR imaging?\n",
      "Radiology 2018;286(1):360–361.\n",
      "\n",
      "\n",
      "2. Kaji Y, Inamura K. Diagnostic ability with\n",
      "\n",
      "abbreviated biparametric and full multiparametric prostate MR imaging: is the use of PIRADS version 2 appropriate for comparison?\n",
      "Radiology 2018;286(2):726–727.\n",
      "\n",
      "3. Kuhl CK, Bruhn R, Krämer N, Nebelung S,\n",
      "\n",
      "Heidenreich A, Schrading S. Abbreviated biparametric prostate MR imaging in men with\n",
      "elevated prostate-specific antigen. Radiology\n",
      "2017;285(2):493–505.\n",
      "\n",
      "4. Weinreb JC, Barentsz JO, Choyke PL, et\n",
      "\n",
      "al. PI-RADS prostate imaging–reporting\n",
      "and data system: 2015, version 2. Eur Urol\n",
      "2016;69(1):16–40.\n",
      "\n",
      "5. Stanzione A, Imbriaco M, Cocozza S, et al.\n",
      "\n",
      "Biparametric 3T magnetic resonance imaging for prostatic cancer detection in a\n",
      "biopsy-naïve patient population: a further\n",
      "improvement of PI-RADS v2? Eur J Radiol\n",
      "2016;85(12):2269–2274 [Published correction appears in Eur J Radiol 2017;87:125.].\n",
      "\n",
      "6. Rud E, Baco E. Re: Jeffrey C. Weinreb,\n",
      "\n",
      "Jelle O. Barentsz, Peter L. Choyke, et al. PIRADS Prostate Imaging—reporting and data\n",
      "system: 2015, version 2. Eur Urol 2016;69:1640. Is contrast-enhanced magnetic resonance\n",
      "imaging really necessary when searching for\n",
      "prostate cancer? Eur Urol 2016;70(5):e136.\n",
      "\n",
      "7. Barth BK, De Visschere PJL, Cornelius A, et\n",
      "\n",
      "al. Detection of clinically significant prostate\n",
      "cancer: short dual-pulse sequence versus\n",
      "standard multiparametric MR imaging—a\n",
      "multireader study. Radiology 2017;284(3):\n",
      "725–736.\n",
      "\n",
      "\n",
      "Erratum\n",
      "\n",
      "\n",
      "**Originally published in:**\n",
      "\n",
      "Radiology 2018;287(1):29–36\n",
      "DOI: 10.1148/radiol.2017171240\n",
      "\n",
      "Thyroid Imaging Reporting and Data\n",
      "System (TI-RADS): A User’s Guide\n",
      "\n",
      "Franklin N. Tessler, William D.\n",
      "Middleton, and Edward G. Grant\n",
      "\n",
      "**Erratum in:**\n",
      "\n",
      "Radiology 2018;287(3):1082\n",
      "DOI:10.1148/radiol.2018184008\n",
      "\n",
      "Figure 9 legend should read as follows:\n",
      "Transverse sonogram in a 52-year-old\n",
      "woman shows a benign follicular nodule with a smooth margin (arrows). The\n",
      "nodule was assigned 2 points for solid\n",
      "composition and 1 for isoechogenicity,\n",
      "for a total of 3 points (TR3).\n",
      "\n",
      "\n",
      "-----\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "display_markdown(print(tirads_md))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "llm-env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
